Since most patients require 816 weeks to find their optimal dose, a flat rate ensures you won't face escalating costs as you increase your medication
Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, et al
These findings are particularly intriguing given the FDAs warnings about the potential increased risk of thyroid cancer, specifically medullary thyroid carcinoma, in patients treated with the GLP-1 receptor agonists [6, 7]
Wang, R
These lawsuits claim the manufacturers didnt adequately warn patients of the potential dangers
Standard labs check TSH alone, which misses subclinical thyroid dysfunction and autoimmune thyroid conditions